Announcements Trials
Browse Landscape

Status

Completed 229Terminated 94Recruiting 79Active not recruiting 40Unknown 33Withdrawn 21Not yet recruiting 10Suspended 3Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 6Pancreatic Neoplasms 4Ovarian Neoplasms 4Sarcoma 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Melanoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chordoma 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Neoplasm Metastasis × Genitourinary × Clear all
NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Pfizer

Available
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡